Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy Volunteers

Model scores of the 29,894 trials active now.

Model score 6% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (176 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: tolerabilitysubjectschildeffectivethe patient
  Phrases that lowered it: healthyscreeningthe effecteffect ofthe pharmacokinetics
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 5.3% (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Maximum age: 79 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 147 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 66.7% (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 0% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, psychiatry: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 3 (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of the Pharmacokinetics and Safety of TPN171H Tablets in Subjects With Mild ,Moderate Hepatic Insufficiency and Normal Liver Function NCT05185011 · started 2021 · scored riskier than 2% of active trials completed
• A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems NCT05731908 · started 2023 · scored riskier than 8% of active trials completed
• A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function NCT02524717 · started 2015 · scored riskier than 2% of active trials completed
• Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function NCT01923870 · started 2013 · scored riskier than 7% of active trials completed
• Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment NCT05856513 · started 2023 · scored riskier than 3% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.